TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is willing and able to complete the micturition diary and questionnaires correctly~* Patient has symptoms of overactive bladder for ≥ 3 months~* Patient must experience frequency of micturition on average ≥ 8 times per 24-hour period during the 3-day micturition diary period~* Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence during the 3-day micturition diary period~Exclusion Criteria:~* Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control~* Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Patient has an indwelling catheter or practices intermittent self-catheterization~* Patient has diabetic neuropathy~* Patient has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs~* Patient receives non-drug treatment including electro-stimulation therapy~* Patient has severe hypertension~* Patient has a known or suspected hypersensitivity to YM178, other beta-adrenoreceptor (ß-AR) agonists, or any of the other inactive ingredients~* Patient has been treated with any investigational drug or device within 30 days~* Patient had an average total daily urine volume \> 3000 mL as recorded in the 3-day micturition diary period~* Patient has serum creatinine of \>150 μmol/L, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x upper limit of normal range (ULN), or Gamma glutamyl transferase (γ-GT) \> 3x ULN~* Patient has a clinically significant abnormal electrocardiogram (ECG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo tablets orally once a day for 12 weeks
- Mirabegron 50 mg (Type: EXPERIMENTAL): Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
- Mirabegron 100 mg (Type: EXPERIMENTAL): Participants received mirabegron 100 m tablets, orally once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: - The decision to initiate treatment with commercially available BIAsp 30 has been made by the patient and the treating physician before and independently from the decision to include the patient in this study - Patients selected by their physician for participation in the study, who are likely to be able and willing to pay for the BIAsp 30 treatment for at least 12 weeks from baseline visit as assessed by the treating physician - Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) - Male or female greater than or equal to 18 years at time of informed consent - Diagnosed with T2DM and treated with BHI in vials for at least three consecutive months at time of informed consent Exclusion Criteria: - Previous participation in this study. Participation is defined as having given informed consent in this study - Concurrent participation in any other clinical trial or study - Patients previously treated with insulin analogues - Known or suspected hypersensitivity to study product (or any of the excipients of the study product; a full list of excipients is provided in Summary of product characteristics (SmPC) of NovoMix® 30) or related products - Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation - Patients who are unable to read or write (illiterate)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Participants with Type 2 Diabetes Mellitus (Type: None): Participants will be prescribed and treated with commercially available BIAsp 30 according to routine clinical practice at the discretion of the treating physician, independent of this study. The study will gather data over the course of routine treatment on willingness to pay for BIAsp 30 in FlexPen® or Penfill®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have completed four months of maintenance treatment in the SP515 (NCT00244387) double-blind trial~Exclusion Criteria:~* Subjects who had an ongoing serious adverse event from SP515 (NCT00244387) double-blind trial that was assessed as related to study medication

- Gender: ALL
- Minimum Age: 31 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): Rotigotine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Different Insole Types in Painful Flexible Flatfoot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* minimum subtalar pronation of 5 degrees while standing (tibiocalcaneal angle, measured with goniometer),~* minimum of + 6 points on the foot posture index,~Exclusion Criteria:~* treatment of the foot for at least six months,~* leg length discrepancy of more than 1 cm,~* history of lower extremity surgery, and no disease that could affect lower extremity biomechanics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- CAD/CAM (Type: EXPERIMENTAL): 8-week follow-up with CAD/CAM insole and home based exercise program
- Semi-custom (Type: EXPERIMENTAL): 8-week follow-up with semi-custom insole and home based exercise program
- Control (Type: PLACEBO_COMPARATOR): 8-week follow-up with placebo insole and home based exercise program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged ≥3 years;~* Proven legal identity;~* Participants or (and) guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;~Exclusion Criteria:~* Prior vaccination with influenza vaccine of the current year;~* History of influenza within 6 months prior to study entry;~* Axillary temperature \> 37.0 °C;~* History of allergy to any vaccine, or any ingredient of the experimental vaccine, especially eggs, egg albumin, etc.;~* Serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc.;~* Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness;~* Autoimmune disease or immunodeficiency/immunosuppressive, or any immunosuppressant receipt within 6 months prior to the study entry;~* History of asthma, thyroidectomy, angioedema, diabetes or malignancy;~* No spleen, or functional no spleen, or splenectomy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental group-phase I (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Experimental group-phase III (Type: EXPERIMENTAL): Quadrivalent influenza vaccine
- Control group-1-phase III (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Victoria strain)
- Control group-2-phase III (Type: ACTIVE_COMPARATOR): Trivalent influenza vaccine (contains B/Yamagata strain)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Azithromycin in Treatment of Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have provided written informed consent to participate in the study in accordance with the local ethics committee regulations~* Have a confirmed diagnosis of bronchiectasis (by HRCT) Aged 18 years or over Have chronic sputum production, defined as a greater than 45 mililitres volume produced in the 1 week prior to study entry.~* Be able to perform reproducible spirometry~* Be in a relatively stable disease state in the 6 weeks prior to entry, as defined by the absence of the following: respiratory exacerbations requiring hospitalisation, change in cough and/or sputum production, new or increased hemoptysis, more than 10% weight loss, use of additional antibiotic courses~Exclusion Criteria:~* Subjects will be excluded if one or more of the following criteria occur. The subject: Is an investigator, or an immediate family member of an investigator~* Has a confirmed diagnosis of cystic fibrosis, as evidenced by genetic analysis or a sweat test result more than 60mmol/L~* Has a primary immunodeficiency Is a pregnant or lactating female Has had a respiratory exacerbation requiring hospitalisation or additional course of antibiotics in the 6 weeks prior to study entry~* Has been prescribed or used oral steroids on any occasion for the 3 months prior to study entry.~* Has been using mucolytic agents on any occasion for the 2 months prior to study entry Has active tuberculosis~* Has an active malignancy, including melanoma (other skin carcinomas excluded)~* Has a history of significant liver disease or insufficiency Has a significant history of drug abuse (including alcohol abuse) or mental illness Has a known intolerance or allergy to macrolides~* Has been participating in another interventional drug study in the 3 months prior to enrolment into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin and Placebo for Azithromycin (Type: ACTIVE_COMPARATOR): Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
- Placebo for Azithromycin (Type: PLACEBO_COMPARATOR): In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for 6 months or greater~* Currently taking stable diabetes medication for 3 months or greater~* HbA1c between 7-10%~* LDL-cholesterol greater than 70 mg/dL~* Women must not be pregnant, lactating, or planning to become pregnant within 30 days after last dose of study medication; and must be postmenopausal, surgically sterile, or willing to use 1 acceptable form of birth control during the study through 30 days after the last dose of study medication~Exclusion Criteria:~* Body mass index \> 40 kg/m2~* History of documented clinically significant cardiovascular disease~* Fasting triglycerides \> 400 mg/dL~* History of Type 1 diabetes~* Uncontrolled hypothyroidism, liver dysfunction, renal dysfunction, gastrointestinal condition that may affect drug absorption, hematologic or coagulation disorder or active malignancy~* History of drug or alcohol abuse within 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bempedoic acid + Ezetimibe FDC (Type: EXPERIMENTAL): Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Oral Tablet, Placebo oral capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Smart Phone Based Telemonitoring on Blood Pressure Among Hypertensive Patients in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All hypertensive patients aged 30 or above and using smart phone~2. Agrees to participate in this pilot study~3. required to attend structured HBPM education program and assessed competent in self BP measurement~Exclusion Criteria:~1. Patients could not use the smart phone independently, such as mentally or physically incapacitated.~2. Patients are not competent in verbal or written communication.~   -

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Smart phone based telemonitoring of HBP (Type: EXPERIMENTAL): 1. . Patients do HBP monitoring~2. . record their BP readings into the smart phone with downloaded application.
- Enhanced usual care (Type: ACTIVE_COMPARATOR): 1. . Patients to do HBP measurement~2. . Record BP readings in their diary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic constipation~* Male or female ages 18-75 years~* Non-pregnant, non-lactating female~Exclusion Criteria:~* Drug-induced constipation~* Subjects suffering from secondary causes of chronic constipation, such as:~* Endocrine disorders, e.g. hypopituitarism, hypothyroidism, hypercalcemia, pseudohypoparathyroidism, pheochromocytoma or glucagon-producing tumors, unless these are controlled by appropriate medical therapy.~* Metabolic disorders, e.g. porphyria, uremia, hypokalemia or amyloid neuropathy, unless these are controlled by appropriate medical therapy~* Neurological disorders, e.g. Parkinson's disease, cerebral tumors, cerebrovascular accidents, multiple sclerosis, meningocele, aganglionosis, hypoganglionosis, hyperganglionosis, autonomic neuropathy or neuropathy due to chemotherapy, spinal cord injury, Chaga's disease, or major depression~* Surgery.~* Subjects with insulin-dependent diabetes mellitus~* Rectal evacuation disorder/outlet obstruction~* Subjects with intestinal perforation or obstruction~* Severe renal impairment~* Subjects with a history of alcohol or drug abuse~* Subjects with lactose intolerance~* Subjects with clinically significant cardiac, vascular, liver, pulmonary, endocrine, neurological or psychiatric disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prucalopride (Type: EXPERIMENTAL): None
- PEG 3350 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥ 18 years of age, with a confirmed diagnosis of cystic fibrosis~* Subjects with gating G551D CFTR mutation on at least one allele in the CFTR gene~* Subjects currently receiving treatment with ivacaftor on a stable regimen or not on a treatment regimen with ivacaftor, for at least 2 weeks prior to screening~* Weight ≥ 40.0 kg~* Subjects on stable concomitant treatment regimen for at least 4 weeks prior to baseline (excluding ivacaftor)~* Pre- or post-bronchodilator FEV1 ≥ 40% of predicted normal~* Subject will have to use highly effective contraceptive methods~Exclusion Criteria:~* On an ivacaftor-containing treatment regimen and unable or unwilling to discontinue ivacaftor for the washout and treatment periods of the study~* Concomitant use of antifungal drugs within 4 weeks of baseline~* A history of a clinically meaningful unstable or uncontrolled chronic disease~* Liver cirrhosis and portal hypertension~* Any significant change in the medical regimen for pulmonary health within 4 weeks of baseline~* Unstable pulmonary status or respiratory tract infection or changes in therapy for pulmonary disease within 4 weeks of baseline~* Abnormal liver function~* Clinically significant abnormalities on ECG~* History of malignancy, solid organ/haematological transplantation~* Abnormal renal function~* Participation in another experimental therapy study within 30 days or 5 times halflife

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3 (Type: EXPERIMENTAL): GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* female participants, age \>/=18 years~* advanced, inflammatory or early stage unilateral invasive breast cancer~* HER2-positive breast cancer~* baseline left ventricular ejection fraction (LVEF) \>/=55%~Exclusion Criteria:~* metastatic disease (Stage IV) or bilateral breast cancer~* previous anticancer therapy or radiotherapy for any malignancy~* other malignancy, except for carcinoma in situ of the cervix, or basal cell carcinoma~* clinically relevant cardiovascular disease~* current chronic treatment with corticosteroids of \>10mg methylprednisolone or equivalent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T+P Concomitant Anthracycline-based chemotherapy (Type: EXPERIMENTAL): 5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
- T+P Sequential Anthracycline-based chemotherapy (Type: EXPERIMENTAL): FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
- T+P Concomitant Non-Anthracycline chemotherapy (Type: EXPERIMENTAL): Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete